{"log_id": 6485065779693187173, "direction": 0, "words_result_num": 47, "words_result": [{"probability": {"variance": 3e-06, "average": 0.998525, "min": 0.994449}, "location": {"width": 227, "top": 232, "height": 28, "left": 208}, "words": "接受过治疗的成年患者"}, {"probability": {"variance": 0, "average": 0.998665, "min": 0.998665}, "location": {"width": 25, "top": 268, "height": 25, "left": 1152}, "words": "件"}, {"probability": {"variance": 0.000159, "average": 0.995672, "min": 0.921678}, "location": {"width": 811, "top": 283, "height": 29, "left": 210}, "words": "研究907:富马酸替诺福韦二吡呋酯+标准背景治疗(SBT)与安慰剂+标准背景治"}, {"probability": {"variance": 1.3e-05, "average": 0.995051, "min": 0.991215}, "location": {"width": 67, "top": 316, "height": 24, "left": 211}, "words": "疗对比"}, {"probability": {"variance": 5e-06, "average": 0.998904, "min": 0.986765}, "location": {"width": 834, "top": 365, "height": 28, "left": 209}, "words": "研究907是一个为期24周、双盲、安慰剂对照的多中心试验,在550名接受过治疗的"}, {"probability": {"variance": 1.7e-05, "average": 0.998396, "min": 0.979769}, "location": {"width": 804, "top": 393, "height": 30, "left": 210}, "words": "受试者中将富马酸替诺福韦二吡呋酯加至稳定的抗逆转录病毒药物背景治疗方案中"}, {"probability": {"variance": 9.8e-05, "average": 0.997051, "min": 0.938032}, "location": {"width": 835, "top": 422, "height": 31, "left": 210}, "words": "经过24周的盲法试验治疗后,对所有继续参加试验的受试者,给予开放标签的富马酸"}, {"probability": {"variance": 0.000173, "average": 0.994711, "min": 0.92405}, "location": {"width": 799, "top": 453, "height": 30, "left": 209}, "words": "替诺福韦二吡呋酯,再持续24周。受试者基线CD4细胞计数平均值为427个细胞"}, {"probability": {"variance": 0.002401, "average": 0.98347, "min": 0.690987}, "location": {"width": 828, "top": 484, "height": 26, "left": 209}, "words": "/mm3(范围23~1385),基线血浆HIV-1RNA中位值为2340(范围50~75,000)拷"}, {"probability": {"variance": 0.003344, "average": 0.980447, "min": 0.73617}, "location": {"width": 831, "top": 511, "height": 28, "left": 211}, "words": "贝/毫升,先前接受HIV-1治疗的平均时间为5.4年。受试者平均年龄为42岁,85%为"}, {"probability": {"variance": 0.000263, "average": 0.992294, "min": 0.92464}, "location": {"width": 456, "top": 542, "height": 26, "left": 211}, "words": "男性,69%为白人,17%为黑人,12%为西语裔"}, {"probability": {"variance": 0.003733, "average": 0.982554, "min": 0.631726}, "location": {"width": 795, "top": 640, "height": 30, "left": 214}, "words": "48周期间HIV-1RNA<400拷贝/毫升的受试者百分比以及受试者结果总结见表11"}, {"probability": {"variance": 0.003742, "average": 0.912874, "min": 0.859935}, "location": {"width": 49, "top": 696, "height": 25, "left": 210}, "words": "表11"}, {"probability": {"variance": 0.000299, "average": 0.992863, "min": 0.934112}, "location": {"width": 254, "top": 695, "height": 26, "left": 410}, "words": "随机治疗结果(研究907)"}, {"probability": {"variance": 2e-06, "average": 0.998071, "min": 0.996662}, "location": {"width": 44, "top": 741, "height": 21, "left": 563}, "words": "24周"}, {"probability": {"variance": 4e-06, "average": 0.996644, "min": 0.994222}, "location": {"width": 42, "top": 741, "height": 20, "left": 773}, "words": "48周"}, {"probability": {"variance": 6e-06, "average": 0.997823, "min": 0.992932}, "location": {"width": 83, "top": 741, "height": 21, "left": 880}, "words": "24~48周"}, {"probability": {"variance": 0, "average": 0.99973, "min": 0.999306}, "location": {"width": 60, "top": 775, "height": 23, "left": 892}, "words": "安慰剂"}, {"probability": {"variance": 0, "average": 0.999944, "min": 0.999937}, "location": {"width": 42, "top": 806, "height": 23, "left": 220}, "words": "结果"}, {"probability": {"variance": 0, "average": 0.795692, "min": 0.795692}, "location": {"width": 39, "top": 802, "height": 19, "left": 481}, "words": " TDF"}, {"probability": {"variance": 0, "average": 0.999654, "min": 0.999084}, "location": {"width": 58, "top": 801, "height": 22, "left": 613}, "words": "安慰剂"}, {"probability": {"variance": 0, "average": 0.914035, "min": 0.914035}, "location": {"width": 41, "top": 802, "height": 19, "left": 758}, "words": " TDF"}, {"probability": {"variance": 0, "average": 0.999824, "min": 0.99969}, "location": {"width": 43, "top": 802, "height": 21, "left": 900}, "words": "过渡"}, {"probability": {"variance": 0.000925, "average": 0.959522, "min": 0.929112}, "location": {"width": 17, "top": 828, "height": 18, "left": 511}, "words": "68"}, {"probability": {"variance": 3.3e-05, "average": 0.992324, "min": 0.984795}, "location": {"width": 62, "top": 825, "height": 21, "left": 891}, "words": "到TDF"}, {"probability": {"variance": 0.023272, "average": 0.873835, "min": 0.581801}, "location": {"width": 54, "top": 851, "height": 18, "left": 895}, "words": "N=170"}, {"probability": {"variance": 0, "average": 0.999803, "min": 0.999606}, "location": {"width": 77, "top": 910, "height": 18, "left": 227}, "words": " hiv-1 RN"}, {"probability": {"variance": 0.000456, "average": 0.985235, "min": 0.934168}, "location": {"width": 118, "top": 930, "height": 23, "left": 228}, "words": "400拷贝/毫升"}, {"probability": {"variance": 0.013872, "average": 0.90559, "min": 0.739541}, "location": {"width": 37, "top": 920, "height": 21, "left": 622}, "words": "11%"}, {"probability": {"variance": 1e-06, "average": 0.999036, "min": 0.998113}, "location": {"width": 33, "top": 920, "height": 20, "left": 762}, "words": "28%"}, {"probability": {"variance": 3e-05, "average": 0.995711, "min": 0.98799}, "location": {"width": 37, "top": 920, "height": 19, "left": 904}, "words": "30%"}, {"probability": {"variance": 8.7e-05, "average": 0.993366, "min": 0.972982}, "location": {"width": 103, "top": 967, "height": 22, "left": 221}, "words": "病毒学失败2"}, {"probability": {"variance": 8e-06, "average": 0.9982, "min": 0.992355}, "location": {"width": 149, "top": 1002, "height": 25, "left": 222}, "words": "因为不良事件停药"}, {"probability": {"variance": 0, "average": 0.999727, "min": 0.999486}, "location": {"width": 20, "top": 1003, "height": 20, "left": 490}, "words": "3%"}, {"probability": {"variance": 6.3e-05, "average": 0.991791, "min": 0.983841}, "location": {"width": 21, "top": 1002, "height": 20, "left": 914}, "words": "5%"}, {"probability": {"variance": 4e-06, "average": 0.998135, "min": 0.994972}, "location": {"width": 163, "top": 1037, "height": 28, "left": 220}, "words": "由于其他原因中断3"}, {"probability": {"variance": 0, "average": 0.999938, "min": 0.999938}, "location": {"width": 20, "top": 1041, "height": 19, "left": 494}, "words": "%"}, {"probability": {"variance": 0, "average": 0.999663, "min": 0.999663}, "location": {"width": 20, "top": 1038, "height": 20, "left": 916}, "words": "%"}, {"probability": {"variance": 0.002344, "average": 0.983112, "min": 0.73182}, "location": {"width": 640, "top": 1073, "height": 24, "left": 244}, "words": "分别为第24周和第48周HIV-1RNA<400拷贝毫升和没有中止先前研究药物的受试者"}, {"probability": {"variance": 0.008856, "average": 0.958327, "min": 0.579718}, "location": {"width": 674, "top": 1100, "height": 23, "left": 245}, "words": "分别为第24周和第48周HIV-1RNA≥400拷贝/毫升疗效失败或HIV-1RNA值缺失的受试者"}, {"probability": {"variance": 3e-06, "average": 0.998627, "min": 0.993928}, "location": {"width": 481, "top": 1128, "height": 21, "left": 248}, "words": "包括失访、受试者中途退出、依从性不良、违反方案以及其他原因"}, {"probability": {"variance": 0.000164, "average": 0.993996, "min": 0.930611}, "location": {"width": 876, "top": 1189, "height": 35, "left": 215}, "words": "与安慰剂组相比,治疗24周时的富马酸替诺福韦二吡呋酯组受试者HIV1RNA<50"}, {"probability": {"variance": 0.014333, "average": 0.964186, "min": 0.419222}, "location": {"width": 835, "top": 1224, "height": 30, "left": 211}, "words": "拷贝/毫升的比例较高(分别为19%和1%)。至第24周,富马酸替诺福韦三吡呋组"}, {"probability": {"variance": 0.001255, "average": 0.986136, "min": 0.799688}, "location": {"width": 807, "top": 1253, "height": 29, "left": 220}, "words": "CD4细胞绝对计数平均变化为+11个细胞/m3,安慰剂组为-5个细胞/mm3。在第48"}, {"probability": {"variance": 1.9e-05, "average": 0.997001, "min": 0.979437}, "location": {"width": 747, "top": 1282, "height": 28, "left": 214}, "words": "周,富马酸替诺福韦二吡呋酯组CD4细胞绝对计数平均变化为+4个细胞/mm"}, {"probability": {"variance": 5.4e-05, "average": 0.997296, "min": 0.954566}, "location": {"width": 836, "top": 1332, "height": 29, "left": 213}, "words": "经过24周治疗,富马酸替诺福韦二吡呋酯组有1名受试者、安慰剂组没有受试者出现"}, {"probability": {"variance": 0.000637, "average": 0.980491, "min": 0.928484}, "location": {"width": 189, "top": 1364, "height": 26, "left": 213}, "words": "新的CDCC类事件"}], "language": 3}